22.12.2023 -
Gilead has exclusive rights for the advancement and commercialization of anti-IL18 binding protein antibodies targeting various tumor types. Gilead commits to a...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)